AstraZeneca's Zomig nasal spray gets first launch in Sweden
AstraZeneca's new nasal spray formulation of its migraine drug Zomig(zolmitriptan) has been introduced in Sweden, its first market. Additional European launches are expected through the remainder of 2002, while regulatory submissions for the product in the USA and Japan are imminent, according to the firm.
Overall, AstraZeneca's Zomig franchise achieved sales of $277 million in 2001 (Marketletter February 4), and it holds second place in the migraine market behind GlaxoSmithKline's Imigran/Imitrex (sumatriptan), which had 2001 sales of $1.09 billion. GSK already offers an intranasal formulation of sumatriptan in the USA and several European countries, and is working towards developing it for the Japanese market (Marketletters passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze